Therefore, the current study aims to retrospectively compare the efficacy and safety of NCRs (3 + 7+Midostaurine and 3 + 7+GO) vs. an FLAI regimen in a population of low- or intermediate-risk NPM1-mutated AML patients. Here, NPM1 is linked to acute myeloid leukemia.